Chat
Feedback
Settings

Settings

Goto Application

3,430 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(JCZSFCLRSONYLH-QYVSTXNMSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 343
1.20250206785ANTIGEN DELIVERY PLATFORMS
US - 26.06.2025
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No 18952185 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor Michael FRANTI

This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.

2.WO/2025/131119CANCER VACCINES AND USES THEREOF
WO - 26.06.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/CN2024/141468 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor HU, Gang
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express a cancer antigen (e.g., PRAME). Also provided herein are methods for treating a cancer.
3.WO/2025/137379METHODS AND COMPOSITIONS FOR STEM CELL DIFFERENTIATION
WO - 26.06.2025
Int.Class C12N 5/071
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
 Appl.No PCT/US2024/061164 Applicant GC THERAPEUTICS, INC. Inventor CABRAL, Katelyn A.
The present disclosure describes methods, kits, compositions, or pharmaceutical comprising engineered cells configured to express one or more transcription factors that promote cellular phenotypes comprising one or more improved liver functions, where such improved liver function is greater than that of a primary hepatocyte or a wild-type hepatocyte.
4.WO/2025/137275NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME
WO - 26.06.2025
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/US2024/061026 Applicant MODERNATX, INC. Inventor AZMI, Ishara
The present disclosure provides novel CRISPR-associated (Cas) nucleases, as well as polynucleotides (e.g., DNA and RNA polynucleotides) encoding the same, host cells containing such nucleases and polynucleotides, and methods of using the foregoing compositions to effectuate genome editing.
5.20250207163METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS
US - 26.06.2025
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
 Appl.No 18850185 Applicant Molecular Assemblies, Inc. Inventor Patrycja A. Hopkins

Methods for the synthesis of polynucleotides using polymerases nucleotide analogs with labile terminator groups that allow stepwise addition of nucleotides are described. These nucleotide analogs may have a modification on 3′, 2′, or 3′-2′-bridged hydroxyl groups or on nucleobase moieties and can be used in the synthesis of natural or modified polynucleotides suitable for use in biological systems. The labile terminator groups are removed under mild conditions or by enzymes. They are accepted as substrates by polymerases. The synthesis may be carried out on a surface.

6.20250205167NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME
US - 26.06.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 18850325 Applicant SAIL BIOMEDICINES, INC. Inventor Alessandra BARTOLOZZI

The disclosure relates to novel ionizable lipids and lipid compositions and pharmaceutical compositions comprising these ionizable lipids that can be used in the delivery of therapeutic agent.

7.WO/2025/132839INFLUENZA VIRUS VACCINES
WO - 26.06.2025
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/EP2024/087475 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor BITTNER-SCHRADER, Zsófia
The present invention is inter alia directed to immunogenic compositions comprising: (a) a first hemagglutinin (HA) antigen or a first nucleic acid, suitably mRNA, encoding the first HA antigen wherein the first HA antigen is derived from a strain of Influenza virus; and (b) a second HA antigen or a second nucleic acid, suitably mRNA, encoding the second HA antigen wherein the second HA antigen is derived from a strain of Influenza virus, wherein (a) and (b) are different, and wherein the ratio of (a):(b) is greater than 5:1. The present invention is also directed to vaccines and kits or kits-of-parts comprising such. Immunogenic compositions, vaccines and kits-of-parts provided herein are suitable for use as a medicament, in particular, for use in the treatment or prophylaxis of an infection with an Influenza virus, suitably an Influenza A and/or Influenza B.
8.20250207207TAXONOMIC SIGNATURES AND METHODS OF DETERMINING THE SAME
US - 26.06.2025
Int.Class C12Q 1/689
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6888for detection or identification of organisms
689for bacteria
 Appl.No 18851355 Applicant Baylor College of Medicine Inventor Tor Savidge

Methods of data analysis, methods of detection, methods of treatment, compositions, and kits associated with treatment of diarrheal disorders are disclosed herein. Inventive concepts disclosed herein can assist stake holders in relieving patient suffering by identifying appropriate therapeutic regimens in an individualized and/or accurate manner.

9.WO/2025/133951IONIZABLE LIPIDS SUITABLE FOR LIPID NANOPARTICLES
WO - 26.06.2025
Int.Class C07F 7/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
7Compounds containing elements of Groups 4 or 14 of the Periodic Table
02Silicon compounds
08Compounds having one or more C-Si linkages
18Compounds having one or more C-Si linkages as well as one or more C-O-Si linkages
 Appl.No PCT/IB2024/062841 Applicant GENEVANT SCIENCES GMBH Inventor CHEN, Kent Tsung Jeng
The present disclosure provides nitrogen-containing silicon ether ionizable lipid compounds and lipid nanoparticles including the ionizable lipid. The disclosure further relates to lipid nanoparticles including a provided ionizable lipid compound together with a phospholipid, e.g., a phospholipid that includes at least one unsaturated tail and a head group having a positively charged nitrogen. The provided materials are particularly beneficial in applications involving delivery of a nucleic acid. The disclosure also provides pharmaceutical compositions and methods including the provided ionizable lipids and/or lipid nanoparticles.
10.WO/2025/129186CLOSTRIDIOIDES DIFFICILE VACCINE AND METHODS OF USE
WO - 19.06.2025
Int.Class A61K 39/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
08Clostridium, e.g. Clostridium tetani
 Appl.No PCT/US2024/060394 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor ALAMEH, Mohamad
The present disclosure provides compositions (e.g., pharmaceutical compositions, e.g., RNA-LNP vaccines) for delivery of C. difficile antigens and related technologies (e.g., components thereof and/or methods relating thereto).
# -